Changes in FDA, Cannabis Policies and AI Developments

In the latest episode of Holland & Knight's Public Policy & Regulation Group "Eyes on Washington" podcast series, Healthcare & Life Sciences attorneys Michael Werner and Sara Klock examine pivotal shifts in U.S. Food and Drug Administration (FDA) regulations.This episode explores updates in three crucial areas: the regulation of laboratory developed tests (LDTs), the proposed reclassifying of cannabis to a Schedule III drug by the U.S. Drug Enforcement Administration (DEA) and the FDA's evolving approach to artificial intelligence (AI). It also covers the FDA's revised guidance on new dietary ingredient notifications (NDINs) for dietary supplements. The discussion provides a comprehensive overview of these significant regulatory updates, breaking down potential impacts and exploring opportunities for industry engagement in influencing upcoming changes.